The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase I/II study of olaparib plus vorinostat/GemBuMel with autoSCT in R/R lymphomas
Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and results of a single-center Phase I/II (NCT03259503) study investigating the use of olaparib plus vorinostat and gemcitabine/busulfan/melphalan (GemBuMel) with autologous stem cell transplantation (autoSCT) in heavily pre-treated relapsed/refractory (R/R) lymphomas. Excellent overall response rate (ORR), complete response (CR) and event-free survival (EFS) rates, and a manageable toxicity profile were reported with this combination, including in patients who had been exposed to CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Affimed: Other: Scientific advisory Board, Research Funding; Secura Bio: Research Funding; Astra Zeneca: Research Funding.
